This is not short-term play but, I can guarentee you no one is shorting this stock at .035. :>) This is a stock that you buy at this price and tuck it your draw for a year. Top people in the field are working on this device and there is no other machine of its kind on the market. I'm told it has already saved two lives, by keeping the patient alive till they got liver transplant. Clinicals begin this year and as positive news is released on each test, the price will rise dramatically. It says 2-5 years to FDA approval. I think sooner than later. The people in the company are not interested in hype so they tend to be cautious. Anyway check it out yourself at www.exten.com. I'm interested in your opinions.
Sybiolr: Synthetic Bio-Artificial Liver technology...
Imagine a device that can do for liver failure what renal dialysis does for kidney failure, a device that would remove toxins from the blood. For years researchers worldwide have searched for a way to replicate the functions of the body's most complex organ, the liver.
Exten Industries, Inc., has created such a device. Known as the SYBIOLr synthetic bio-liver, the device operates outside the body, doing for the liver what dialysis machines do for people with kidney disease--and more.
"As the indications for liver transplantation have increased and as donor organs have become scarcer, the need for an artificial liver has become more imperative."
John J. Brems, M.D., F.A.C.S. Director of Transplantation at Loyola University Medical Center
PROTOTYPE TESTING
Pending funding, clinical trials will be directed toward FDA approval for clinical applications in the US. Sybiolr could also provide pharmaceutical companies with a safe, inexpensive way to test new drugs, an application which may not require FDA approval.ÿ
Yale University and Loyola University in Chicago have both received one of the fourth generation Sybiol machines. As part of the Food and Drug Administration approval process, both universities will be conducting animal studies utilizing the device. These studies are designed to prove the safety of the Sybiol machine for future use on humans. Dr. Amy Friedman, Chief, Liver Transplantation Services, Division of Organ Transplantation, at Yale University is heading up Yale's program; while Dr. Brems will guide studies at Loyola.
Medical Need Indicates Market Potential
"Patients with liver failure usually die within 96 hours..."
unless a device could be made available to do for patients with liver failure what renal dialysis can do for kidney failure.
That device could be the Sybiolr synthetic bio-liver device that Exten Industries' Xenogenics Corporation subsidiary is taking into FDA trials. By circulating patients' blood through a replaceable cartridge interfaced with constantly recalculating living porcine liver cells, the device removes toxins from the blood. This could give the liver a chance to regenerate and recover from the shock of disease, poisoning, or drug overdoses. Further, treatment with Sybiolr could help liver transplant patients prepare for surgery and enjoy post-transplant support.
Medical need increasing
A device capable of providing liver functions and sustaining patients until transplant is of paramount need, as about 20% of those awaiting a donor organ die. Hepatitis is reaching epidemic proportions and is expected to surpass AIDs as a cause of death by the year 2010. Hepatitis B affects over 350 million people worldwide, killing 2 million annually. Liver disease is the eighth leading disease-related cause of death in the United States. Over 44,000 deaths occur annually in the US alone due to liver and gall bladder disease. One in ten Americans has some form of liver disease. So an artificial means of supporting liver function could potentially save hundreds of lives every year in the US alone and improve care and treatment for millions.
Market potential
The potential for an artificial liver support device is projected to be in excess of $1 billion dollars annually in the US. The international market is expected to be larger, as incidence of liver disease is much greater in some countries. |
